CAR T-cell therapy for indolent lymphoma: a new treatment paradigm?
Mené sur 153 patients atteints d'un lymphome non hodgkinien indolent réfractaire ou récidivant, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité de l'axicabtagène ciloleucel, une immunothérapie à base de lymphocytes CAR-T ciblant CD19 (durée médiane de suivi : 17,5 mois)
Comprised of heterogeneous, chronic lymphomas that generally have a lingering, protractedcourse, indolent non-Hodgkin lymphoma remains difficult to cure. In those with earlydisease progression and recurrent relapse when responses to second-line and third-linetherapies are suboptimal, and a high risk of transformation to more aggressive lymphomasis seen, novel approaches are needed. In The Lancet Oncology, Caron A Jacobson and colleagues report the results of the ZUMA-5 trial, a multicentre, single-arm, phase 2 studyof axicabtagene ciloleucel for treatment of relapsed or refractory indolent non-Hodgkinlymphoma. This pivotal study led to the US Food and Drug Administration acceleratingapproval of axicabtagene ciloleucel as the first chimeric antigen receptor (CAR) T-celltherapy available for relapsed or refractory indolent follicular lymphoma in March,2021
The Lancet Oncology , commentaire, 2020